Q-omics provides the consensus-scored ITPRID2 profile across patient tissues and cancer cell-line models. ITPRID2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITPRID2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ITPRID2 protein abundance shows 23,059 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where ITPRID2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITPRID2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITPRID2 survival associations across molecular data types. ITPRID2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITPRID2 RNA expression–survival associations across cancer types. High ITPRID2 expression shows unfavorable associations in BLCA, LGG, KICH and HNSC, but favorable associations in KIRC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITPRID2 RNA expression.
This table summarizes ITPRID2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ITPRID2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITPRID2 shows lower tumor expression in LUAD, COAD, THCA, KICH and KIRC and higher tumor expression in HNSC. The HNSC box plot shows higher ITPRID2 RNA expression in tumor versus normal tissue (log2 FC = +1.736, t-test p < 0.001).
This table shows molecular features associated with ITPRID2 in patient tissues and cancer cell lines. In patient samples, ITPRID2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ITPRID2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
